Biohit

2,86

EUR

+1,06 %

4.840 følger denne virksomhed

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview

Finansielt overblik og estimater

Investor consensus

+1,06%

0%

+24,89%

+24,89%

+25,99%

+43%

+71,26%

+25,44%

-45%

Biohit is a medical technology company. The company develops and manufactures laboratory equipment, supplies, and diagnostic analysis systems adapted for research, care, and industrial laboratories. In addition to the main activities, technical support, maintenance, and training services are offered within the mentioned work area. The largest presence is in the Nordic market. The company is headquartered in Helsinki.

Markedsværdi

43,42 mio. EUR

Aktieomsætning

6,96 t EUR

P/E (adj.) (25e)

19,07

EV/EBIT (adj.) (25e)

13,93

P/B (25e)

2,98

EV/S (25e)

2,08

Udbytteafkast, % (25e)

1,31 %

Coverage

Anbefaling

Akkumulér

Kursmål

3.20 EUR

Opdateret

02.03.2025

Antti Siltanen

Analytiker

Latest research

Seneste analyse

Released: 03.03.2025

Seneste omfattende analyse

Released: 15.01.2025

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

4.6

2025

Generalforsamling '25

6.8

2025

Delårsrapport Q2'25

Risiko

Business risk

Valuation risk

Lav

Høj

Alle

Analyse

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse25.3.2025, 10.10

Biohit Plc - Managers' transactions - Hendolin

Selskabsmeddelelse19.3.2025, 07.30

Publication of Biohit Oyj Annual Report 2024

Selskabsmeddelelse19.3.2025, 07.30

Publication of Biohit Oyj Remuneration Report 2024

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Selskabsmeddelelse13.3.2025, 13.32

Biohit Oyj - Managers' Transactions

Biohit: Safety margin available again

Analyse3.3.2025, 09.15 af

Biohit: Safety margin available again

Biohit's share price has fallen and the risk/reward ratio has become attractive again.

Biohit H2'24: Progress despite a bumpy road

Analyse13.2.2025, 07.41 af

Biohit H2'24: Progress despite a bumpy road

Biohit's figures were already largely known based on preliminary data and the H2 report was in line with expectations.

Selskabsmeddelelse12.2.2025, 07.30

BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2024

Biohit H2’24 preview: Growth subdued in H2, but profitability excellent

Analytikerkommentar11.2.2025, 07.13 af

Biohit H2’24 preview: Growth subdued in H2, but profitability excellent

Based on releases in recent months, we expect growth from the launch of the new product, distribution partnerships and a new market opening around the middle of the year, referred to by the company in its Q3’24 IR blog.

Pressemeddelelse6.2.2025, 09.00

BIOHIT and Restalyst announce collaboration to improve non-invasive early gastric cancer detection

Pressemeddelelse31.1.2025, 09.30

BIOHIT introduces the FAEX™ Sample System for stool sample collection and handling

Analytikerkommentar17.1.2025, 07.07 af

New distribution rights for Biohit

Biohit announced on Thursday that it has signed a distribution agreement with Biomedal for the distribution of celiac disease diagnostic tests in selected European countries.

Pressemeddelelse16.1.2025, 09.00

BIOHIT secures European distribution rights for Biomedal’s gluten immunogenic peptide tests

Omfattende analyse15.1.2025, 12.56 af

Biohit extensive report: Profitable growth through diagnostics

Biohit has achieved a successful turnaround and is targeting strong growth of 15-20% over the 2024-28 strategy period. We expect the company's earnings to continue to grow in the coming years, supported by the development of new markets and new product launches.

Analytikerkommentar9.1.2025, 06.53 af

Biohit test receives further proof of its effectiveness in the UK

Biohit announced on Wednesday the results of a study of GastroPanel® for the diagnosis of gastric precancerous conditions. The GastroPanel® test on a blood sample identified patients at risk of gastric cancer requiring further examinations with over 90% accuracy.

Pressemeddelelse8.1.2025, 08.30

Approval of Biohit’s GastroPanel® test for use by the British National Health Service (NHS) takes a major step forward

Analyse23.12.2024, 06.50 af

Biohit: Performance surprised positively

Biohit issued a profit warning related to revenue, but despite this, the new 2024 earnings guidance (EBIT percentage 16-18%) clearly exceeded our expectations.

Analytikerkommentar20.12.2024, 06.50 af

Positive earnings surprise revealed under Biohit revenue guidance downgrade

Profitability has seen some ups and downs, so the sustainability of H2's excellent performance is still uncertain.

Selskabsmeddelelse19.12.2024, 09.00

Insider information, profit warning: Biohit lowers its guidance for 2024

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Video2.12.2024, 14.00

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Selskabsmeddelelse27.11.2024, 12.00

Biohit Oyj’s Financial Reporting and Annual General Meeting in 2025

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.